Anti-CD20 monoclonal antibody that targets CD20-positive B cells in NHL and promotes NK cell–mediated ADCC.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B cells and depletes them via NK cell antibody-dependent cellular cytotoxicity (through Fc gamma receptor IIIa/CD16), complement-dependent cytotoxicity, and induction of apoptosis.
Rituximab binds CD20 on B cells and induces killing via NK cell–mediated ADCC (FcγRIIIa/CD16), complement-dependent cytotoxicity, and can also trigger apoptosis upon crosslinking.
Anti-CD38 monoclonal antibody that targets myeloma plasma cells and engages NK cell ADCC.
Human IgG1-kappa anti-CD38 monoclonal antibody that binds CD38 on myeloma and other hematologic tumor cells, inducing direct cytotoxicity and Fc-mediated killing (NK-cell ADCC via CD16, macrophage ADCP, and complement-dependent cytotoxicity), while depleting CD38+ immunosuppressive cells; it can also inhibit CD38 ectoenzyme activity, reducing adenosine-mediated immune suppression.
Daratumumab binds CD38 on target cells and induces Fc-mediated killing—NK-cell ADCC (via CD16), macrophage ADCP, and complement-dependent cytotoxicity (CDC); it can also trigger apoptosis upon crosslinking.
Anti-CD38 monoclonal antibody that targets myeloma plasma cells and facilitates NK cell–mediated ADCC.
Human(ized) IgG1 anti-CD38 monoclonal antibody that binds CD38 on myeloma/plasma cells and induces tumor cell killing via NK cell–mediated antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis; also inhibits CD38 ectoenzyme activity.
Isatuximab binds CD38 on target cells and induces killing via NK cell–mediated ADCC, complement-dependent cytotoxicity, and direct apoptosis.
Anti-CD117 (c-Kit) monoclonal antibody used for recipient hematopoietic stem cell depletion to create marrow space and facilitate engraftment.
Humanized anti‑CD117 (c‑Kit) monoclonal antibody that blocks stem cell factor (SCF) binding and KIT signaling on hematopoietic stem cells, leading to HSC depletion in the marrow niche to create space and facilitate donor engraftment.
Binds CD117 and blocks SCF–KIT survival signaling, causing depletion/apoptosis of KIT+ hematopoietic stem cells; Fc engagement can recruit immune effectors (ADCC/ADCP) to kill bound cells.
Anti-CD52 monoclonal antibody used for lymphodepletion of T, B, and NK cells.
Humanized IgG1 anti-CD52 monoclonal antibody that binds CD52 on mature lymphocytes and some myeloid cells, triggering complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity to deplete T, B, and NK cells and induce immunosuppression.
Alemtuzumab binds CD52 and triggers complement-dependent cytotoxicity and Fc-mediated ADCC (and phagocytosis), leading to lysis of CD52+ lymphocytes and some myeloid cells.